EKSPERIMENTAL QANDLI DIABETDA JIGAR MIKROSOMAL OKSIDLANISH FENOTIPINING UGLEVOD VA LIPID ALMASHINUVIGA TA'SIRI: SITOXROM P450 FAOLLIGI VA METABOLIK BUZILISHLAR O'RTASIDAGI BOG'LIQLIK

Nurmuhammad Mamazulunov; Gavharoy Sodiqova

doi:10.5281/zenodo.20823254

Авторы

Mamazulunov Nurmuhammad Husanboy o'g'li Biologik kimyo va farmatsevtika kafedrasi katta o'qituvchisi Qo'qon universiteti Andijon filiali, Andijon, O'zbekiston
Sodiqova Gavharoy Erkinjon qizi Qo'qon universiteti Andijon filiali, Davolash ishi yo'nalishi, 2-bosqich talabasi

Аннотация

Streptozotsin (STZ) bilan keltirilgan eksperimental qandli diabet (QD) modelida jigar mikrosomal oksidlanish fenotipining — tez (TO) va sekin (SO) oksidlovchilarning — uglevod hamda lipid almashinuvi ko'rsatkichlariga qanday ta'sir ko'rsatishini aniqlash. Wistar zotli erkak kalamushlar (n=32) streptozotsin (60 mg/kg, in peritoneumga) yordamida diabetik model shakllantirildi. Antipirin testi asosida hayvonlar TO (n=12) va SO (n=10) subguruhlariga ajratildi, nazorat guruhi (n=10) amalda sog'lom hayvonlardan iborat bo'ldi. Glyukoza, insulin, HbA1c, HOMA-IR, lipidlar spektri, MDA, SOD, katalaza va CYP2E1 aktivligi o'lchandi. Ma'lumotlar Kruskal-Wallis va Mann-Whitney U testlari yordamida tahlil qilindi (SPSS v.26). SO guruhida och qorindagi glyukoza darajasi nazoratga nisbatan 4,3 barobar ortdi (22,4±1,8 vs 5,2±0,3 mmol/L, p<0,001), GTT-120 da normalizatsiya kuzatilmadi. TO guruhida esa CYP2E1 faolligi nazorat qiymatidan 2,8 barobar yuqori chiqdi (1,18±0,09 vs 0,42±0,03 nmol/min/mg), MDA 2,2 barobar, SOD esa 2,3 barobar pasaydi (p<0,001). Lipid spektrida TO guruhida PZLP-XS ustunlik qilsa (4,2±0,3 mmol/L), SO guruhida jigarda diffuz trigliserid to'planishi kuzatildi.

Ключевые слова:

qandli diabet mikrosomal oksidlanish fenotipi sitoxrom P450 CYP2E1 uglevod almashinuvi lipidlar peroksidlanishi oksidlanishli stress streptozotsin jigar metabolizmi dislipidemiya.

Библиографические ссылки

International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels: IDF; 2021. Available from: https://www.diabetesatlas.org [Accessed 2024 Mar 15].

DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015;1:15019. doi:10.1038/nrdp.2015.19.

Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest. 2016;126(1):12-22. doi:10.1172/JCI77812.

Guengerich FP. Cytochrome P450 and chemical toxicology. Chem Res Toxicol. 2008;21(1):70-83. doi:10.1021/tx700079z.

Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103-141. doi:10.1016/j.pharmthera.2012.12.007.

Leung TM, Nieto N. CYP2E1 and oxidant stress in alcoholic and non-alcoholic liver disease. J Hepatol. 2013;58(2):395-398. doi:10.1016/j.jhep.2012.08.018.

Abdelmegeed MA, Song BJ. Functional roles of protein nitration in acute and chronic liver diseases. Oxid Med Cell Longev. 2014;2014:149627. doi:10.1155/2014/149627.

Raza H, John A, Shafarin J. N-Acetylcysteine Attenuates Oxidative Stress and Liver Injury in Streptozotocin-Induced Diabetic Rats. Ann N Y Acad Sci. 2016;1374(1):46-52. doi:10.1111/nyas.13040.

Song X, Qian Y, Chen H, Li X, Li F, Ma L. CYP2E1 promotes hepatic steatosis and inflammatory response by regulating NLRP3 inflammasome activation and autophagy. Biochem Pharmacol. 2020;172:113745. doi:10.1016/j.bcp.2019.113745.

Elsner M, Tiedge M, Lenzen S. Mechanism underlying resistance of human pancreatic beta cells against toxicity of streptozotocin and alloxan. Diabetologia. 2003;46(12):1713-1714. doi:10.1007/s00125-003-1241-x.

Dorne JL, Walton K, Renwick AG. Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review. Food Chem Toxicol. 2005;43(2):203-216. doi:10.1016/j.fct.2004.10.002.

Aebi H. Catalase in vitro. Methods Enzymol. 1984;105:121-126. doi:10.1016/S0076-6879(84)05016-3.

Kessova I, Cederbaum AI. CYP2E1: biochemistry, toxicology, regulation and function in ethanol-induced liver injury. Curr Mol Med. 2003;3(6):509-518. doi:10.2174/1566524033479609.

Li F, Lu J, Cheng J, Wang L, Matsubara A, Krausz KW, et al. Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy. Nat Med. 2013;19(4):418-420. doi:10.1038/nm.3104.

Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017;15(1):45. doi:10.1186/s12916-017-0806-8.

Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes. 2003;52(6):1364-1370. doi:10.2337/diabetes.52.6.1364.

Guo Y, Cho HY, Whitaker RH, Wan M, He B. CYP2E1 regulation by lipid peroxidation end-products in the context of its own induction. Free Radic Biol Med. 2018;115:92-103. doi:10.1016/j.freeradbiomed.2017.11.022.

Tirmenstein MA, Hu CX, Scully SM, Fariss MW. Effects of succinate on mitochondrial function and extent of lipid peroxidation in vitro. Chem Biol Interact. 1997;105(3):181-193. doi:10.1016/S0009-2797(97)00042-1.

Christensen M, Andersson K, Dalen P, Mirghani RA, Muirhead GJ, Nordmark A, et al. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther. 2003;73(6):517-528. doi:10.1016/S0009-9236(03)00052-4.

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapentaenoic acid for hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. doi:10.1056/NEJMoa1812792.

География читателей

2 Просмотры

0 Загрузки PDF

2 Стран

EKSPERIMENTAL QANDLI DIABETDA JIGAR MIKROSOMAL OKSIDLANISH FENOTIPINING UGLEVOD VA LIPID ALMASHINUVIGA TA'SIRI: SITOXROM P450 FAOLLIGI VA METABOLIK BUZILISHLAR O'RTASIDAGI BOG'LIQLIK

Авторы

Аннотация

Ключевые слова:

Библиографические ссылки

География читателей

Загрузки

Опубликован

Выпуск

Раздел

Лицензия

Как цитировать

Издатель

Контакты

Ссылки